The Journal of Drug Assessment is an open access journal that publishes study types on a range of drug therapeutics of interest to the clinical medicine and research communities.
The journal aims to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The journal’s objective is to help facilitate improvements in patient health by facilitating a collaborative and honest approach to publication.
The journal welcomes smaller studies, preliminary and pilot studies, results from trials that have not met their endpoints and studies with confirmatory findings from Phase I–Phase IV trials. It also welcomes review articles and meta-
The journal’s scope — combined with the transparent and rigorous peer review process — make certain that papers are accepted based on their scientific merit (i.e., technically sound, well-written, comprehensive reports), not on the novelty or impact of the results. In addition, the rapid publication timeline allows for online publication within 7-9 weeks of submission, whilst always ensuring total transparency of the peer-review process and disclosure of financial and other relevant relationships for all submitted manuscripts.
The Journal of Drug Assessment publishes:
Smaller and lower-impact studies and early trial data
Null or negative study results in addition to incomplete, inconclusive or controversial results
Confirmatory studies and updates to previous research
Case studies in clinical practice, involving new and existing drugs
Reviews on new and existing drugs, novel study designs, research and pharmacoeconomic outcomes
Full-length original articles and meta-analyses that report the results of Phase I–IV studies on pharmaceutical products and medical devices in all drug classes, therapeutic areas and disease states (including approved and unapproved products, therapeutic diagnostic/theranostic products and over-the-counter medicines)
Brief research reports that meet the above criteria and have the same elements as a full-length paper, but are shorter, and provide more concise information in each element, with fewer illustrations
Editorials commenting on new developments in pharmaceutical regulatory affairs, new policies, health outcomes and drug manufacturing, and controversial clinical and preclinical findings
Letters to the Editor as correspondence to the Editor on previously published work
The journal operates a single-blind peer review policy.
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
JDA is indexed on PubMed Central. As an open-access journal, each paper will be submitted to PubMed Central, which automatically feeds all open access papers to PubMed/Medline, therefore articles contained within JDA will be available for download via Pub-Med/Medline. The archive of published papers will be fully searchable by title, abstract, keywords, authors, publication year on our website.
In time and with approvals received, copies of each published paper may be supplied to other indexers (ie, EMBASE, Coch-rane, CAB, CINAHL, Biosis, International Pharmaceutical Abstracts, Pharm-line, HEED and others). Papers also will be supplied to national depositories and major libraries.
Open access
Journal of Drug Assessment is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![HRB Open Research is a platform for HRB-funded researchers to rapidly publish their research outputs in an open and accessible way.]({"type":"image" , "src" : "/sda/112432/HRB-KB.jpg"})